Featuring experts from

Featured Logos

Number of experts listed:
2928

Visit us on Facebook Visit us on Twitter

‘Good’ virus for common infection

Friday, 31 July 2020

Antibiotic-resistant diabetic foot ulcer application

Adelaide researchers are showing how viruses can be used to save lives, developing the potential use of bacteriophages in bandages to treat life-threatening golden staph infections which may not respond to traditional antibiotics.

Targeting multidrug-resistant Staphylococcus aureus (‘golden staph’) in diabetic foot ulcers, Flinders University microbiology researchers have joined infectious diseases and pharmaceutical partners to show the usefulness of a possible ‘phage cocktail’ therapy on wound infections.

A phage (or bacteriophage) is a virus capable of infecting a bacterial cell and is capable of being used in a range of medical applications including as a therapy against ‘superbugs’.  

Bacteriophages (phages, viruses that infect bacteria) represent an alternative or adjunct therapy to antibiotics, with S aureus a common and particularly virulent pathogen often found to be resistant and limited for antimicrobial treatment options.

“Diabetic foot ulcers are very dangerous and when infected can lead to amputation and even death,” says Flinders University Associate Professor Peter Speck, who is Secretary of the Australasian Virology Society.

“The next step in our research is to bind phages to a dressing to make a truly antibacterial dressing, with specific activity against golden staph. The technology exists to make such a dressing, with a big advantage being that bound phages remain viable for a year even when stored at room temperature, making this approach ideal for use in hospitals and clinics – even in rural and remote settings.” 

Co-author on a new paper in BMC Microbiology, Flinders PhD Legesse Garedew Kifelew says the results of the sound treatment in mice were very promising.

“This study demonstrates that phage therapy could be a potential alternative in combating antibiotic-resisant bacterial infections,” says Mr Kifelew, who works in infectious disease management at the Queen Elizabeth Hospital and has ties to St Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia. 

“The phages effectively decreased the bacterial load and significantly improved wound healing in in multi-drug resistant S aureus infection – similar or superior to the currently prescribed antibiotic treatment,” he says.

With diabetes on the rise, the global burden of diabetic foot ulcers (DFUs) is also affecting up to 26.1 million people each year, with these ulcers the cause of almost 90% of limb amputations. The five-year mortality rate following foot amputation due to DFUs has been estimated at up to 74%.

Based on 2015 prevalence data from the International Diabetes Federation, it is estimated that foot ulcers develop in 9.1 million to 26.1 million people with diabetes annually worldwide.

In the US, the annual cost of managing DFU infections is estimated at an additional US$9–13 billion over the cost of diabetes itself. In England, it is estimated that the annual cost of managing DFUs exceeds the total cost of breast, prostate and lung cancers combined.

The paper, ‘Efficacy of phage cocktail AB-SA01 therapy in diabetic mouse wound infections caused by multidrug-resistant Staphylococcus aureus‘ (2020) by LG Kifelew, MS Warner, S Morales, L Vaughan, R Woodman, R Fitridge, JG Mitchell and P Speck has been published in BMC Microbiology (Springer Nature). DOI: 10.1186/s12866-020-01891-8

 

For more information contact:

Name: Associate Professor Peter Speck, microbiology researcher, College of Science and Engineering, Flinders University Tel: +61 8 8201 2765  M: +61 (0) 422 917 657
 
Name: Legesse Garedew Kifelew, PhD candidate Flinders University and St Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia. 
Mob: +61 (0)449 512 434
Email: legessegk@gmail.com Skype: legesse.garedew2
 
Tania Bawden, Media Adviser, Office of Communication, Marketing and Engagement, Flinders University
Tel: +61 8 8201 5768   Mob: +61 (0)434 101 516